news
Could viral vector shortages disrupt the COVID-19 vaccine roll-out?
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
List view / Grid view
Janssen
Filter the results
news
J&J submits COVID-19 vaccine data to FDA for emergency authorisation
J&J have submitted Phase III trial data in their application to the FDA for emergency authorisation of their COVID-19 vaccine candidate.
news
J&J COVID-19 vaccine shows success in interim analysis of Phase III trial
An interim analysis has shown that the COVID-19 vaccine developed by J&J is safe and effective at preventing the coronavirus in adults.
video
HIV treatments: an interview with Dr Jaime Oliver Vigueras
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
news
Antibiotics market set to generate revenue of $58,800 million by 2027
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
article
Vaccine innovation in the UK: SMEs and national capabilities
The UK Government is supporting the development of COVID-19 vaccines, including two innovative UK vaccine candidates. In this article, we describe the history of these candidates and introduce innovative small and medium enterprises (SMEs) and national capabilities that are working to combat the current pandemic and improve the UK’s vaccine…
news
EMA begins rolling review of Janssen’s COVID-19 vaccine candidate
The European Medicines Agency's CHMP has started a rolling review of Ad26.COV2.S, Johnson & Johnson's COVID-19 vaccine.
news
UK secures total of 357 million doses of various COVID-19 vaccines
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
news
J&J initiates second Phase III trial of COVID-19 vaccine candidate
J&J has initiated a global Phase III clinical trial to study JNJ-78436735, a vaccine candidate for the prevention of COVID-19.
news
J&J to supply Europe with 200 million doses of COVID-19 vaccine
J&J has agreed that it will supply the EU with 200 million doses of its COVID-19 vaccine candidate following regulatory approval.
news
CDMO to conduct fill and finish manufacture of COVID-19 vaccine
US outsourcing organisation GRAM is set to undertake the aseptic fill and finish manufacture of J&J's COVID-19 vaccine candidate.
news
Phase III trial of J&J COVID-19 vaccine candidate enrols first volunteers
A Phase III clinical trial to evaluate J&J's COVID-19 vaccine in multiple countries has enrolled its first patients.
news
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
news
J&J agrees to manufacture 100 million doses of COVID-19 vaccine for US
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
article
Five patent issues that European biosimilar developers should consider before entering the US market
As patents on originator biologic medicines begin to expire, there are growing opportunities for biosimilars to enter the market at lower prices. Joshua Whitehill, Natasha Daughtrey and Grace Truong discuss key aspects of US patent law that European developers should consider before entering the American market.